Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial

Background: Chronic low back pain (LBP) is a growing health problem. Non-steroidal anti-inflammatory drugs ( NSAIDs) are used to treat this condition, but have not demonstrated efficacy beyond 2 weeks, and no studies have shown that NSAIDs produce durable improvements in disability. Methods: To evaluate the efficacy and durability of effect of etoricoxib for chronic LBP, a randomized, double blind, placebo-controlled trial was conducted at 46 centres. Three hundred and twenty-five patients with chronic LBP requiring treatment with an NSAID or paracetamol were randomized 1: 1: 1 to etoricoxib 60 mg (n = 109), 90 mg (n = 106), or placebo (n = 110), daily for 3 months. Pre-specified endpoints over 3 months included LBP intensity scale ( visual analog scale 0 - 100 mm) time-weighted average change from baseline, the Roland - Morris Disability Questionnaire (RMDQ), the LBP bothersomeness scale, patient and investigator global assessments, and measures of quality of life. Results: Both etoricoxib groups experienced significant reductions in LBP intensity at 4 weeks versus placebo [ -15.15 mm and -13.03 mm for 60 and 90 mg, respectively, probability ( p) <0.001 for each], which was maintained over 3 months. Treatment resulted in significant improvement from baseline compared to placebo in RMDQ scores ( etoricoxib 60 mg, -2.82 and 90 mg, -2.38, p<0.001 for each) over 12 weeks and most other efficacy endpoints. There were no significant differences between treatments in incidence of adverse events (AEs) or discontinuations due to AEs. Conclusion: Etoricoxib provided significant relief of symptoms and disability associated with chronic LBP detected at 1 week, confirmed at 4 weeks, and maintained over 3 months. Reductions in chronic LBP severity corresponded to improvements in physical functioning and quality of life. All treatments were generally well tolerated.